J Urol Oncol > Volume 22(2); 2024 > Article |
|
Grant/Fund Support
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2020R1A2C2011428).
Research Ethics
This single-center retrospective case series was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (IRB approval number: 2211-028-1375).
Conflicts of Interest
CK, the Editor-in-Chief of Journal of Urologic Oncology, is the corresponding author of this article. However, he played no role whatsoever in the editorial evaluation of this article or the decision to publish it. The other authors have nothing to disclose.
Author Contribution
Conception and design: SHK, CWJ, GJC, CK; Administrative support: SHK, CWJ, SHJ; Provision of study materials and patients: JCW, HDY, JHK, HHK, CK; Collection and assembly of data: SHK, CWJ, JHH; Data analysis and interpretation: SHK, CWJ, MTD; Funding acquisition: GJC; Manuscript writing: SHK, CWJ, MTD, JHH, SHJ, HDY, JHK, HHK, GJC, CK; Final approval of manuscript: SHK, CWJ, MTD, JHH, SHJ, HDY, JHK, HHK, GJC, CK.
Characteristic | Value |
---|---|
Age (yr) | 71.8 (65.9-79.1) |
PSA at time of PSMA PET/CT (ng/mL) | 1.77 (0.36-10.75) |
ISUP grade group | |
1 | 14 (6.2) |
2 | 31 (13.8) |
3 | 49 (21.8) |
4 | 70 (31.1) |
5 | 61 (27.1) |
Values are presented as median (interquartile range) or number (%).
Group 1, further work-up for high-risk localized prostate cancer; group 2, de novo metastatic prostate cancer; group 3, biochemical recurrence; group 4, castration-resistant prostate cancer; group 5, others; PSA, prostate-specific antigen; PSMA PET/CT, Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography; ISUP, The international society of urological pathology.
pN (+) | pN (-) | |
---|---|---|
Ga-68 PSMA-11 (+) | 3 | 5 |
Ga-68 PSMA-11 (-) | 4 | 11 |
Sensitivity | Specificity | Accuracy | PPV | NPV | AUC | |
---|---|---|---|---|---|---|
LN (+) | 0.43 | 0.88 | 0.74 | 0.6 | 0.78 | 0.65 |
Ga-68 PSMA-11 PET/CT, gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography; PLND, pelvic lymph node dissection; RTx., radiation therapy; BCR, biochemical recurrence; RPLND, retroperitoneal lymph node dissection; CRPC, castration resistance prostate cancer.
Si Hyun Kim
https://orcid.org/0000-0002-5984-9485
Chang Wook Jeong
https://orcid.org/0000-0002-2200-5019
Minh-Tung Do
https://orcid.org/0000-0003-4936-5660
Jang Hee Han
https://orcid.org/0000-0003-4942-4632
Seung-Hwan Jeong
https://orcid.org/0000-0002-8076-3643
Hyeong Dong Yuk
https://orcid.org/0000-0002-5874-9167
Ja Hyeon Ku
https://orcid.org/0000-0002-0391-2342
Hyeon Hoe Kim
https://orcid.org/0000-0001-6600-4539
Gi Jeong Cheon
https://orcid.org/0000-0002-1360-5186
Cheol Kwak
https://orcid.org/0000-0002-1987-2111